Adlai Nortye (ANL)

Executive Summary

Adlai Nortye (NASDAQ: ANL) is a Cayman Islands-based clinical-stage biopharmaceutical company focusing on oncology, with a pipeline of eight drug candidates across immuno-oncology and targeted therapies. The company's key assets include AN4005 (oral PD-L1 inhibitor) in Phase 1 for advanced solid tumors, AN9025 (RAS inhibitor) in Phase 1 for solid tumors with RAS mutations, and AN0025 (EP4 antagonist) in Phase 1 for esophageal cancer. The pipeline also includes completed Phase 3 trial for buparlisib in head and neck cancer and earlier-stage programs for breast cancer and rectal cancer. Adlai Nortye operates globally with headquarters in Hangzhou, China, and additional offices in New Jersey, USA. As of mid-2026, Adlai Nortye's most advanced programs remain in early clinical stages. The recent initiation of AN9025 Phase 1 trial and ongoing AN4005 dose-escalation study represent key near-term data catalysts. However, the company faces significant risks including high cash burn, reliance on early-stage data, and competitive oncology landscape. The stock trades at approximately $15 per share with a market cap of ~$885 million, reflecting high uncertainty. Recent pipeline updates from completed trials (buparlisib Phase 3) may provide partial de-risking, but no clear path to registration. Investors should monitor AN4005 Phase 1 data expected in late 2026 and any partnership or licensing deals that could validate the platform.

Upcoming Catalysts (preview)

• Q4 2026AN4005 Phase 1 Dose-Escalation Data Readout60% success
• H2 2027AN9025 Phase 1 Initial Safety and Efficacy Data40% success
• 2026Potential Business Development or Licensing Deal30% success